Open original FDA record ↗Recall record
- FDA identifier
- Z-1771-2021
- Company in FDA record
- Medtronic Minimed
- FDA record creation date
- Jun 1, 2021
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Due to a software design issue, under certain conditions, a software fault is detected when a large bolus delivery at quick bolus speed completes. if the user is not aware of the amount of active insulin and delivers an additional bolus, there is a risk of insulin over delivery.
Source facts
- Action
- On 03/15/2021, the Recalling Firm sent an "URGENT MEDICAL DEVICE CORRECTION" Notification via regionally approved methods (e.g. email, registered mail, courier, hand delivery) informing customers that their insulin pump with software version 6.5 that could present pump errors after delivering a large bolus under certain conditions. These errors may occur if All the following conditions are met: 1-The bolus delivery speed is programmed to Quick in the pump settings (default is Standard). 2-The SmartGuard" feature is in use. 3-The pump needs to be on the bolus delivery screen when an auto correction bolus is triggered. Auto corrections are triggered when sensor glucose (SG) is running high and Active Insulin is low. 4-The bolus amount programmed to be delivered is greater than 17.1U. Note: This can be a single bolus greater than 17.1U or a combination of boluses totaling greater than 17.1U. If all the above conditions are met, within 2 minutes of bolus delivery completion, the pump initiates Pump error 53, followed by Pump error 23 alarm. Upon clearing the pump errors, the pump resets and indicates Active Insulin has been cleared. The pump then guides the user to resume operation in Manual Mode. The SmartGuard" status screen indicates the warm-up period has started. After approximately 5 hours, the SmartGuard" feature will be available. Since Active Insulin will display 0.0 units in the pump after experiencing the pump errors above, if the user is not aware of the amount of active insulin and delivers an additional bolus, there is a risk of insulin over delivery, which may result in low blood sugar (hypoglycemia) or severe hypoglycemia. In rare cases, severe hypoglycemia, if left untreated, may lead to a life-threatening situation. As of January 21, 2021, Medtronic has received no reports of serious patient harm or serious injury related to this issue. Customers are instructed to: If their pump screen indicates that Active Insulin has cleare
- Initiated
- 2021-03-15
- Root cause
- Software design
- Distribution
- U.S.(Clinical): AR, CA, CO, CT, FL, GA, ID, MI, MN, TN, TX, and WA O.U.S.: Austria, Bahrain, Belgium, Canary Islands, Chile, Croatia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Gibraltar, Greece, Hungary, Iceland, Ireland, Israel, Italy, Liechtenstein, Luxembourg, Malta, Martinique, Netherlands, New Caledonia, Norway, Poland, Qatar, Reunion, Romania, Slovenia, South Africa, Spain, Sweden, Switzerland, Turkey, and United Kingdom
- Recall number
- Z-1771-2021
- Recall status
- Open, Classified
- CDRH record ID
- 186884
- FDA record created
- 2021-06-01
- Recall event number
- 87735